Search Results - tiansen+li

3 Results

Sort By:

Mini-Bioreactor for Enhanced Organoid Culture

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes. This technology includes a mini-bioreactor designed to improve organoid outcomes in cell culture applications. The bioreactor system is a multi-well, 3D-printed device that...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Kyle Schwab, Tiansen Li

Keywords(s):

Category(s): Application > Research Materials, Application > Non-Medical Devices, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Ophthalmology

RPGR Gene Therapy for Retinitis Pigmentosa

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa. This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Michael Sandberg, Basil Pawlyk, Xinhua Shu, Robin Ali, Alan Wright, Tiansen Li

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, ResearchProducts > Virus/Bacteria, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases

RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa

Abstract: X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene. This technology is poised to advance RPGR or RP2 gene therapy to clinical stage using AAV8 or AAV9 vector carrying human full-length RPGR or RP2-coding...

Published: 5/15/2025 | Updated: 8/2/2023 | Inventor(s): Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna, Tiansen Li

Keywords(s): GENE THERAPY, hereditary ocular disease, Pigmentosa, Retina, Wu

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology